INTRODUCTION
Antimicrobial resistance is of international concern with rising resistance leading to increased hospital lengths of stay, costs, and mortality rates [1, 2] . The World Health Organization, the Infectious Diseases Society of America, the European Centre for Disease Prevention and Control, and the European Medicines Agency have identified multidrug-resistant organisms as one of the leading obstacles in modern medicine [3] [4] [5] . One proposed method of attenuating the rise of resistance is reducing unnecessary antibiotic use through antimicrobial stewardship programs (ASPs) [6] . Studies have reported that 33% to 72% of pediatric patients admitted to a hospital receive antimicrobials [7] [8] [9] [10] [11] . In separate reports, approximately half of the antimicrobials prescribed in healthcare facilities have been considered unnecessary or incorrect [12, 13] . Because the vast majority of studies on antimicrobial stewardship have been conducted in adult facilities, the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America identified research in pediatric settings to be needed [6] . Although reports from a number of pediatric studies have been published [12, [14] [15] [16] [17] [18] [19] [20] [21] , to our knowledge, no study has described the implementation of an ASP in a nonfreestanding children's hospital. Substantial differences between freestanding and nonfreestanding children's hospitals exist, including patient characteristics, medical training programs, and clinical outcomes [22] [23] [24] [25] . Nationally, it is estimated that only 10% of pediatric hospitalizations occur in a freestanding children's hospital [26] , which suggests that research on pediatric antimicrobial stewardship in other facility types is also needed. In 2013, Randall Children's Hospital (RCH) implemented an ASP. The objective of this study was to evaluate the impact of this program on overall antibiotic use.
METHODS

Setting
RCH is a 165-bed tertiary-care, community, nonfreestanding children's hospital located in Portland, Oregon, and includes 24 pediatric intensive care unit (ICU) and 46 neonatal ICU beds. RCH is physically connected to an adult facility and shares a central pharmacy, pharmacy and therapeutics committee, infection-control personnel, and additional resources. Services include all major pediatric subspecialties with the exception of bone marrow and solid organ transplantation and cystic fibrosis care.
As part of the Oregon Antimicrobial Stewardship Collaborative [27] , RCH developed and implemented an ASP with no additional financial or human resources. This program consisted of 2 strategies, (1) engaging physician groups to identify areas for systematic improvement and (2) 72-hour prospective auditing with feedback with a primary goal of optimizing appropriate antibiotic use. The ASP was led by the pediatric infectious diseases group, which comprises 5 physicians who provide infectious diseases consultation; only 1 infectious diseases physician provided consultation services at any given time, and the remainder of these physicians provided hospitalist or administrative services. The pediatric infectious diseases group approached different physician groups to encourage self-evaluation of antibiotic use, adoption of national guidelines and best practices, and upgrading of order sets and protocols. Several systematic changes, including the development of a protocol for antibiotic prophylaxis in pediatric cardiac surgery [28] , adoption of a standardized appendicitis protocol, and revision of the febrile neutropenia order set, occurred because of this engagement.
Prospective auditing and feedback were performed by pediatric pharmacists who provided routine care but did not have specialty training in infectious diseases or receive additional training for this ASP. An automated report was generated in our electronic medical record (EPIC, Epic Systems, Verona, Wisconsin) that identified patients who had been on antibiotics for 72 hours or longer. Pharmacists were asked to review this list daily for antibiotic appropriateness. No ASP-specific protocol was developed to guide the 72-hour review, and the decision on antibiotic appropriateness was made at the discretion of the pharmacist. The pediatric infectious diseases physician who provided infectious diseases consultation was available for discussion of specific patient cases with the pharmacists on a daily basis. If therapy modification was recommended, the pharmacist or pediatric infectious diseases physician communicated it to the providers who were caring for the patient.
Study Design
This quasi-experimental study was conducted from April 2012 to March 2015; prospective auditing and feedback commenced in a systematic fashion in April 2013. Antimicrobials in this analysis included antibiotics used to treat bacterial infections, administered by either the enteral or parenteral route. Because the focus of this program was antibiotics, we excluded antimicrobials used for viral, fungal, parasitic, or mycobacterial infections. Because the ASP was not implemented simultaneously in the neonatal ICU or emergency department, these units were excluded from analysis. All other inpatient units were included. The attached adult facility did not participate in the ASP, so antibiotic use in that facility served as an additional control.
The main outcome of this study was the difference in antibiotic use in the preintervention period and the postintervention period. Other outcomes included differences in drug-acquisition costs, antibiotic use in the pediatric ICU, and differences in the use of specific antibiotics. Antibiotic use was measured as the monthly aggregate of days of therapy (DOT) (defined as each day that an antibiotic was administered [29] ) normalized by 1000 patient-days (DOT/1000 PD). A monthly aggregate case-mix index (CMI) was used to control for average patient severity, as was described previously [7, 30] . To identify any change in clinical outcomes, the monthly average length of stay and monthly mortality rate were analyzed.
Antibiotic use and drug-acquisition costs were extracted from electronic medication administration records, as recommended in the recent Infectious Diseases Society of America guidelines on implementing an ASP [31] , and patient-day data were extracted from hospital census data. These data were validated independently by the pharmacy and information technology departments to ensure accuracy. This study was granted approval by the Legacy Health institutional review board.
Statistical Analysis
Interrupted time-series analysis with ordinary least-squares regression was performed to compare antibiotic use in the preintervention period with that in the postintervention period. This analysis was performed with and without the adult facility serving as an additional control. For further analysis, we examined average monthly antibiotic use by a t-test or Wilcoxon rank-sum test, as was done previously [17] . Visual examination and the Shapiro-Wilk test were used to determine if the data were normally distributed. All statistical analyzes were performed in Stata 13 (Stata Corp, College Station, Texas); a P value of < .05 was considered significant.
RESULTS
A total of 20 099 admissions occurred during the study period, and the average (± standard deviation) length of stay was 4.3 ± 0.5 days. The antibiotics that comprised the greatest percentage of DOTs during the entire study period were first-generation cephalosporins (17.8%), third-generation cephalosporins (15.2%), aminopenicillins (13.4%), clindamycin (9.2%), cefepime (7.9%), and vancomycin (6.6%).
Interrupted time-series analysis revealed that CMI-adjusted antibiotic use in the postintervention period was lower by 16.8% (95% confidence interval [CI], −18.0% to −9.2%; P < .001) relative to that predicted on the basis of preintervention trends ( Figure 1 ). This difference was substantially greater than that identified without adjustment for CMI (−1.1% [95% CI, −3.5% to 1.3%]; P = .35). Including the attached adult facility as an additional control in an interrupted times-series model exaggerated the benefit of the ASP in the postintervention period (−19.3% [95% CI, −20.2% to −18.4%]; P < .001).
Results of an analysis of average monthly antibiotic use confirmed that use was lower in the postintervention period; this was identified in data that were controlled and those that were not controlled for CMI (Table 1) . In contrast to RCH, antibiotic use at the attached adult facility was unchanged (Table 1 ). Significant differences in antibiotic-specific use at RCH are listed in Table 2 . Because it seemed that the use of antibiotics commonly used for surgical prophylaxis was lower in the postintervention period, antibiotic use was analyzed with and without these antibiotics (cefazolin, cefoxitin, and cefotetan). After excluding these antibiotics, antibiotic use in the postintervention period was lower by 11.4% compared to that in the preintervention period (367 ± 23 vs 326 ± 20 DOT/1000 PD per CMI unit, respectively; P = .008). The use of cefazolin, cefoxitin, and cefotetan was lower by 38% in the postintervention period (104 ± 18 vs 64 ± 22 DOT/1000 PD per CMI unit; P = .011). As broad-spectrum antipseudomonal β-lactams are often used interchangeably, we evaluated a composite of cefepime, piperacillin-tazobactam, and meropenem use. The combined use of these agents was similar in both periods (64 ± 6 [preintervention period] vs 70 ± 14 [postintervention period] DOT/1000 PD per CMI unit; P = .45), whereas vancomycin use was lower by 38% (Table 2) .
Average monthly drug-acquisition costs at RCH were lower in the postintervention period than in the preintervention period ($8962 ± $1534 vs $5801 ± $2239 per 1000 PD, respectively; P < .001), which equates to cost savings of approximately $67 000/year over the 2-year postintervention period. Although pharmacy and physician clinicians performed additional tasks for the ASP, additional expenditures were not required, and these tasks were integrated into the workflow, which resulted in no documented costs for this program. The average monthly CMI was greater in the postintervention period by 6.5% than in the preintervention period (1.4 ± 0.1 vs 1.5 ± 0.1 CMI, respectively; P = .03). The mean monthly mortality rates in the preintervention and postintervention periods were similar (0.51% [preintervention period] vs 0.56% [postintervention period]; P = .68), and they were also similar after adjusting for CMI. The average length of stay was longer in the postintervention period than in the preintervention period, but the lengths of stay were similar after adjusting for CMI (2.9 vs 3.0 days per CMI unit, respectively; P = .19).
DISCUSSION
In this study, we found that with limited dedicated resources, a simple ASP can reduce antibiotic use substantially in a nonfreestanding children's hospital. A reduction in antibiotic use was realized with no alteration in mortality rates or lengths of stay. Antibiotic use at the attached adult facility was similar in both periods, which indicates that various external factors, such as hospital policy changes, were unlikely to be responsible for the decreased antibiotic use at RCH.
Most reports of pediatric stewardship interventions are from freestanding or academic children's hospitals [12, [14] [15] [16] [17] [18] [19] [20] [21] . To our knowledge, this is the first report of a hospital-wide implementation of stewardship activities at a nonfreestanding children's hospital. Our hospital used prospective auditing and feedback and clinical guidelines as the main interventions. Although we cannot determine which specific tactic resulted in greater reductions in antibiotic use, it seems that on the basis of our analysis (Figure 1) , there was a large initial decrease in antibiotic use immediately after the intervention. This decrease is likely a result of systematic changes that occurred after physician-group engagement; this result was confirmed by substantial decreases in antibiotics typically used for surgical prophylaxis, which is likely to have been realized by order-set and protocol changes.
Although the use of antipseudomonal agents was similar in the postintervention period, vancomycin use was substantially lower (Table 2 ). In 2013, our hospital modified a protocol to recommend piperacillin-tazobactam as the preferred agent for surgical prophylaxis or treatment for appendectomy and appendicitis, respectively. This change, in addition to drug shortages, was likely to be partially responsible for the higher use of piperacillin-tazobactam. The combined usage of cefepime and meropenem was similar in the postintervention period (64 ± 16 [preintervention period] vs 60 ± 19 [postintervention period] DOT/1000 PD; P = .63), which indicates that antipseudomonal usage seemed to be unaffected by the ASP independent of piperacillin-tazobactam use. It is possible that practitioners are more likely to discontinue vancomycin in the absence of positive culture results for methicillin-resistant Staphylococcus aureus than they are to discontinue antipseudomonal coverage in the absence of positive culture results for Gram-negative organisms. Although some authors have suggested that a 72-hour antibiotic review is ideal [21] , this time might be too delayed to have a significant effect on broad-spectrum antibiotic use at our facility. A 48-hour review might have more of an effect and enable alterations of empiric therapy and more rapid responses to culture-based therapy changes. However, because no added resources were used for this program, there were instances when the pharmacists were unable to review the 72-hour list because of their other patient care tasks and obligations. Additional resources might be needed at our facility to optimize pharmacy workflow and perform a 48-hour prospective review using our current model.
Other studies in pediatric facilities found similar reductions in antibiotic use with ASP implementation [14] [15] [16] [17] . Newland et al [14] reported 7% and 17% reductions in overall use and use of targeted antibiotics, respectively, after implementation of a prospective audit-with-feedback program. Similarly, Di Pentima and Chan [16] reported a reduction in vancomycin doses by approximately 33% after implementation of prospective auditing with feedback targeted at vancomycin. Antibiotic use (DOT/1000 PD) at our facility seems to be slightly lower than that reported from studies that evaluated use at freestanding children's hospitals [14, 17] ; however, data from these other facilities are slightly dated, and use might have been lower during the time period of our study. In addition, RCH does not serve several patient populations that typically have high rates of inpatient antibiotic consumption, such as patients with cystic fibrosis or those who are undergoing bone marrow or solid organ transplantation. Although RCH treats patients with malignancies, patient volumes are likely lower than those at other facilities. Finally, this analysis did not include data from the neonatal ICU. Although comparison to nonfreestanding children's hospitals would be ideal, the lack of published data from these facilities and the differences between our facility and freestanding facilities makes such a comparison of antibiotic use difficult.
Several limitations are present in this study. First, this was a retrospective study with a historical control. Other changes, such as infection-control measures and changes in national guidelines [17] , might have influenced our antibiotic use independent of the ASP. Because antibiotic use at the attached adult facility was similar in the pre-and postintervention periods, hospital-wide changes seem unlikely to have influenced antibiotic use substantially. Second, comparative data from other nonfreestanding children's hospitals would have served as a better control; however, RCH does not participate in a pediatric-specific database, such as the Pediatric Health Information System (Children's Hospital Association) [14] . Third, we did not evaluate the impact of the ASP on antibiotic adverse events or clinical outcomes. Finally, although we identified lower antibiotic use in the postintervention period than in the preintervention period, we cannot determine if all reductions in use were appropriate.
CONCLUSIONS
The results of this study confirm that implementation of a simple stewardship initiative with limited resources at a nonfreestanding children's hospital effectively reduced antibiotic use without having an overt negative effect on overall clinical outcomes. Our results suggest that nonfreestanding children's hospitals can achieve reductions in antibiotic use similar to those at freestanding children's hospitals despite differences in patient characteristics, services offered, and available resources. Although lower antibiotic use was realized, we believe that our ASP would greatly benefit from dedicated resources. Additional study is needed to identify the effect of pediatric stewardship initiatives and their effect on clinical outcomes in specific disease states. Future studies should focus on improving optimal use of antibiotics with a goal of improving clinical outcomes.
Notes
